PT - JOURNAL ARTICLE AU - Alkharaan, Hassan AU - Bayati, Shaghayegh AU - Hellström, Cecilia AU - Olsson, Annika AU - Lindahl, Karin AU - Bogdanovic, Gordana AU - Aleman, Soo AU - Tsilingaridis, Georgios AU - De Palma, Patricia AU - Hober, Sophia AU - Månberg, Anna AU - Nilsson, Peter AU - Pin, Elisa AU - Sällberg Chen, Margaret TI - Persisting Salivary IgG against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys AID - 10.1101/2021.03.13.21253492 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.13.21253492 4099 - http://medrxiv.org/content/early/2021/03/15/2021.03.13.21253492.short 4100 - http://medrxiv.org/content/early/2021/03/15/2021.03.13.21253492.full AB - Background Declining humoral immunity in COVID-19 patients and possibility of reinfections has raised concern. Mucosal immunity particularly salivary antibodies could be short-lived. However, long-term studies are sparse.Methods Using a multiplex bead-based array platform, we investigated antibodies specific to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins in 256 saliva samples from convalescent patients 1-9 months after symptomatic COVID-19 (n=74, Cohort 1), undiagnosed individuals with self-reported questionnaires (n=147, Cohort 2), and individuals sampled pre-pandemic time (n= 35, Cohort 3).Results Salivary IgG antibody responses in Cohort 1 (mainly mild COVID-19) were detectable up to 9 month recovery, with high correlations between spike and nucleocapsid specificity. At 9 months, IgG remained in saliva in majority as seen in blood serology. Salivary IgA was rarely detected at this timepoint. In Cohort 2, salivary IgG and IgA responses were significantly associated with recent history of COVID-19 like symptoms. Salivary IgG also tolerated temperature and detergent pre-treatments.Conclusions Unlike SARS-CoV-2 salivary IgA that appeared short-lived, the specific IgG in saliva appears stable even after mild COVID-19 as noted for blood serology. The non-invasive saliva-based SARS-Cov-2 antibody testing with self-collection at homes may thus serve as a complementary alternative to conventional blood serology.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot a clinical trialFunding StatementThis study was supported by grants to Region Stockholm, Knut and Alice Wallenberg foundation, Science for Life Laboratory (SciLifeLab), Erling-Persson family foundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the human ethical authority (dnr 2020-01702, 2020-06381)in Sweden and complied with the declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during the current study are available from the corresponding author on reasonable request.